image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 16.34
-3.03 %
$ 809 M
Market Cap
-11.35
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one STAA stock under the worst case scenario is HIDDEN Compared to the current market price of 16.3 USD, STAAR Surgical Company is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one STAA stock under the base case scenario is HIDDEN Compared to the current market price of 16.3 USD, STAAR Surgical Company is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one STAA stock under the best case scenario is HIDDEN Compared to the current market price of 16.3 USD, STAAR Surgical Company is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart STAA

image
$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
314 M REVENUE
-2.64%
-12.6 M OPERATING INCOME
-44.88%
-20.2 M NET INCOME
-94.66%
15.7 M OPERATING CASH FLOW
7.75%
-59.2 M INVESTING CASH FLOW
-79.65%
5.72 M FINANCING CASH FLOW
-22.81%
42.6 M REVENUE
-12.99%
-57.4 M OPERATING INCOME
-105.66%
-54.2 M NET INCOME
-58.38%
-5.73 M OPERATING CASH FLOW
-893.15%
35.4 M INVESTING CASH FLOW
281.33%
-948 K FINANCING CASH FLOW
-761.82%
Balance Sheet STAAR Surgical Company
image
Current Assets 368 M
Cash & Short-Term Investments 230 M
Receivables 79.3 M
Other Current Assets 58.2 M
Non-Current Assets 142 M
Long-Term Investments 0
PP&E 122 M
Other Non-Current Assets 19.8 M
45.24 %15.56 %11.42 %23.90 %3.89 %Total Assets$509.5m
Current Liabilities 70.3 M
Accounts Payable 16.7 M
Short-Term Debt 3.94 M
Other Current Liabilities 49.7 M
Non-Current Liabilities 41.9 M
Long-Term Debt 34.8 M
Other Non-Current Liabilities 7.08 M
14.89 %3.51 %44.27 %31.03 %6.31 %Total Liabilities$112.2m
EFFICIENCY
Earnings Waterfall STAAR Surgical Company
image
Revenue 314 M
Cost Of Revenue 74.3 M
Gross Profit 240 M
Operating Expenses 252 M
Operating Income -12.6 M
Other Expenses 7.6 M
Net Income -20.2 M
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)314m(74m)240m(252m)(13m)(8m)(20m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
76.32% GROSS MARGIN
76.32%
-4.02% OPERATING MARGIN
-4.02%
-6.44% NET MARGIN
-6.44%
-5.09% ROE
-5.09%
-3.97% ROA
-3.97%
-6.35% ROIC
-6.35%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis STAAR Surgical Company
image
35m35m30m30m25m25m20m20m15m15m10m10m5m5m00(5m)(5m)(10m)(10m)201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -20.2 M
Depreciation & Amortization 6.89 M
Capital Expenditures -23.4 M
Stock-Based Compensation 27.2 M
Change in Working Capital -5.4 M
Others -1.76 M
Free Cash Flow -7.67 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets STAAR Surgical Company
image
Wall Street analysts predict an average 1-year price target for STAA of $56.4 , with forecasts ranging from a low of $45 to a high of $85 .
STAA Lowest Price Target Wall Street Target
45 USD 175.58%
STAA Average Price Target Wall Street Target
56.4 USD 245.20%
STAA Highest Price Target Wall Street Target
85 USD 420.20%
Price
Max Price Target
Min Price Target
Average Price Target
909080807070606050504040303020201010Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership STAAR Surgical Company
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
17.6 M USD 1
0-3 MONTHS
26.5 M USD 1
3-6 MONTHS
1.95 M USD 1
6-9 MONTHS
50 K USD 1
9-12 MONTHS
7. News
STAAR Surgical Announces Participation in Upcoming Investor Conferences LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2025 Virtual Ophthalmology Forum Date: Tuesday, May 27, 2025 Format: Meetings and Webcast Fireside Chat Webcast: 2:00 PM ET, Webcast Link Wells Fargo 2025 West Coast Bus Tour Date: Thursday, May 29, 2025 Loca. businesswire.com - 1 month ago
STAAR Surgical Announces $30 Million Share Repurchase Authorization LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. “Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and. businesswire.com - 1 month ago
STAAR Surgical Q1: Clouded Outlook Warrants Caution (Rating Downgrade) Sales in China were severely impacted due to inventory de-stocking, but the outlook for the region for H2 2025 looks promising. Global sales ex-China were weak, with management choosing to withdraw the earlier guidance for revenue growth of 9–15%. I expect revenue and earnings of $320 million and $23 million, respectively, for next year, which puts the current valuation at 43.5 times earnings. seekingalpha.com - 1 month ago
STAAR Surgical Company (STAA) Q1 2025 Earnings Call Transcript STAAR Surgical Company. (NASDAQ:STAA ) Q1 2025 Earnings Conference Call May 7, 2025 5:15 PM ET Company Participants Brian Moore - VP, Investor Relations and Corporate Development Stephen Farrell - Chair of the Board, President and CEO Warren Faust - President and COO Deborah Andrews - Interim CFO Conference Call Participants Tom Stephan - Stifel Anthony Petrone - Mizuho Ryan Zimmerman - BTIG Patrick Wood - Morgan Stanley Operator Greetings and welcome to the STAAR Surgical First Quarter 2025 Earnings Webcast. seekingalpha.com - 1 month ago
Staar Surgical (STAA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates Although the revenue and EPS for Staar Surgical (STAA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 month ago
Staar Surgical (STAA) Reports Q1 Loss, Tops Revenue Estimates Staar Surgical (STAA) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to earnings of $0.06 per share a year ago. zacks.com - 1 month ago
STAAR Surgical Reports First Quarter 2025 Results LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin. businesswire.com - 1 month ago
STAAR Surgical Announces Changes to Board of Directors LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has. businesswire.com - 2 months ago
STAAR Surgical to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025 LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the first quarter ended March 28, 2025, on Wednesday, May 7, 2025 after the market close. The Company will also host an earnings call and webcast at 5:15 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 1Q 2. businesswire.com - 2 months ago
Tilman Fertitta, Carl Icahn, and More Insiders Return to the Buy Window Since the beginning of April, market volatility has spiked, due largely to uncertainty about inflation, interest rates, upcoming quarterly reports, and mostly the impact of tariffs and a global trade war on the U.S. 247wallst.com - 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 months ago
STAAR Surgical Announces Realignment of Leadership Structure LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the following changes to right size and realign its leadership structure to better address market needs: Warren Foust, Chief Operating Officer, has been promoted to the newly created role of President and Chief Operating Officer. In this expanded role, Mr. Foust will continue to oversee. businesswire.com - 3 months ago
8. Profile Summary

STAAR Surgical Company STAA

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 809 M
Dividend Yield 0.00%
Description STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Contact 25651 Atlantic Ocean Drive, Lake Forest, CA, 92630 https://www.staar.com
IPO Date Feb. 24, 1992
Employees 1157
Officers Dr. Magda Michna Ph.D. Chief Development Officer and Chief Clinical, Regulatory & Medical Affairs Officer Ms. Nancy Sabin Chief Marketing Officer Mr. Warren Foust President & Chief Operating Officer Mr. Nathaniel B. Sisitsky Esq. Senior Vice President, Chief Legal Officer, General Counsel & Corporate Secretary Mr. James Francese Senior Vice President of Commercial Operations - North America & APAC Mr. Brian Moore Vice President of Investor Relations & Corporate Development Mr. Thomas G. Frinzi Advisor Ms. Deborah J. Andrews Interim Chief Financial Officer Mr. Stephen C. Farrell CFA Chief Executive Officer & Director Dr. Scott D. Barnes M.D. Chief Medical Officer